SELLAS Life Sciences Group, Inc. (SLS)
14.14
+0.92
(+6.96%)
USD |
NASDAQ |
Sep 02, 16:00
14.00
-0.14
(-0.99%)
After-Hours: 20:00
SELLAS Life Sciences Group Research and Development Expense (TTM) : 20.35M for June 30, 2026
Research and Development Expense (TTM) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Research and Development Expense (TTM) Data
| Date | Value |
|---|---|
| June 30, 2026 | 20.35M |
| March 31, 2026 | 17.95M |
| December 31, 2025 | 16.02M |
| September 30, 2025 | 15.73M |
| June 30, 2025 | 15.88M |
| March 31, 2025 | 17.19M |
| December 31, 2024 | 19.10M |
| September 30, 2024 | 19.76M |
| June 30, 2024 | 21.21M |
| March 31, 2024 | 21.94M |
| December 31, 2023 | 24.01M |
| September 30, 2023 | 24.76M |
| June 30, 2023 | 23.22M |
| March 31, 2023 | 22.83M |
| December 31, 2022 | 20.27M |
| September 30, 2022 | 17.82M |
| June 30, 2022 | 18.07M |
| March 31, 2022 | 16.00M |
| December 31, 2021 | 15.67M |
| September 30, 2021 | 15.05M |
| June 30, 2021 | 12.88M |
| March 31, 2021 | 11.70M |
| December 31, 2020 | 9.282M |
| September 30, 2020 | 8.757M |
| June 30, 2020 | 8.189M |
| Date | Value |
|---|---|
| March 31, 2020 | 7.29M |
| December 31, 2019 | 7.285M |
| September 30, 2019 | 8.69M |
| June 30, 2019 | 8.611M |
| March 31, 2019 | 8.822M |
| December 31, 2018 | 8.767M |
| September 30, 2018 | 5.826M |
| June 30, 2018 | 5.174M |
| March 31, 2018 | 5.409M |
| December 31, 2017 | 5.789M |
| September 30, 2017 | 9.697M |
| June 30, 2017 | 12.25M |
| March 31, 2017 | 16.60M |
| December 31, 2016 | 19.86M |
| September 30, 2016 | 20.09M |
| June 30, 2016 | 22.21M |
| March 31, 2016 | 23.32M |
| December 31, 2015 | 23.79M |
| September 30, 2015 | 25.21M |
| June 30, 2015 | 26.72M |
| March 31, 2015 | 27.49M |
| December 31, 2014 | 28.35M |
| September 30, 2014 | 29.17M |
| June 30, 2014 | 25.56M |
| March 31, 2014 | 22.76M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (TTM) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (TTM) Benchmarks
| Savara, Inc. | 86.84M |
| Lite Strategy, Inc. | 0.169M |
| AbbVie, Inc. | 9.714B |
| Marker Therapeutics, Inc. | 8.806M |
| Rezolute, Inc. | 59.77M |